Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A Critical Review of Biological Properties, Delivery Systems and Analytical/Bioanalytical Methods for Determination of Bevacizumab

Full text
Di Filippo, Leonardo Delello [1] ; dos Santos, Karen Cristina [1] ; Hanck-Silva, Gilmar [1] ; de Lima, Felipe Tita [1] ; Gremiao, Maria Palmira Daflon [1] ; Chorilli, Marlus [1]
Total Authors: 6
[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, BR-14800903 Araraquara, SP - Brazil
Total Affiliations: 1
Document type: Review article
Source: CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY; v. 51, n. 5, p. 445-453, JUL 4 2021.
Web of Science Citations: 3

Bevacizumab is a chimeric monoclonal human-murine antibody originated from murine monoclonal antibody (muMAb A4.6.1) with the human immunoglobulin IgG1. BVZ binds the extracellular portion of vascular endothelial growth factor receptors (VEGFR), which have tyrosine kinase activity. The mechanism of action of BVZ involves binding to VEGFR, Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2), inducing homodimerization of two receptor subunits, and, consequently, autophosphorylation of their tyrosine kinase domains located inside the cytoplasm. With the advent of nanostructured systems it is increasingly necessary to look for safe analytical methods, ensuring the reliability of the results obtained by them, becoming essential to ensure the quality of medicines. In this work, the incorporation of bevacizumab in to different drug delivery systems was presented. Moreover, detailed investigation was performed about methods for qualitative and quantitative analyses of bevacizumab, including, biological fluids, and drug delivery systems, were investigated. Most recently high performance liquid chromatography coupled with various detectors, liquid chromatography, mass spectrometry and ELISA were used for this purpose. Thus, this review was performed to evaluate the benefits of bevacizumab carried by nanostructured systems and the analytical methods available for detection and quantification of these drugs. (AU)

FAPESP's process: 18/18488-3 - Potential evaluation of nanostructured lipid carriers functionalized with bevacizumab for delivery of docetaxel in the treatment of glioblastoma
Grantee:Leonardo Delello Di Filippo
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 18/23430-4 - Evaluation of the potential of bevacizumab-functionalized liposomes or hyaluronic acid for incorporation of abiraterone in the treatment of prostate cancer
Grantee:Kaio Pini Santos
Support Opportunities: Scholarships in Brazil - Post-Doctoral